Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
1d
Boxer Mark Weinman, who returned from a nearly 21-year layoff to win a professional bout at age 50, has died. Weinman, from the borough of Queens in New York City, died Feb. 8 in Mesa, Arizona, his ...
Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.
The following is a summary of “Development of the pulmonary fibrosis, pulmonary vascular resistance, six minute walk distance, B-type natriuretic peptide, age (PVD-B65) risk score for patients with ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Low total cholesterol levels were tied to an increased risk of death for pulmonary fibrosis patients with disease of unknown ...
Hosted on MSN7d
Tabla Maestro Zakir Hussain Excluded from Grammy's 'In Memoriam' Tribute, Sparks BacklashGrammy Awards faced criticism for omitting four-time Grammy-winning tabla maestro Zakir Hussain from its 'In Memoriam' segment. Hussain, who passed away on December 15, 2024, due to idiopathic ...
Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...
Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback